Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

181.14 +4.08 (+2.30%)
Official Closing Price Updated: 7:00 PM EST, Nov 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
71 72 Next >
Citigroup, Dell And 2 Other Stocks Insiders Are Selling
The S&P 500 closed almost flat on Wednesday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
Is Merck Stock a Screaming Buy After This $11 Billion Acquisition?
Merck's move into immunology is a risky proposition. 
Via The Motley Fool
3 Stocks You Can Keep Forever
Three solid profitable companies that are growing their businesses and their dividends. 
Via The Motley Fool
3 Reasons Why I Regret Selling AbbVie
Having the knowledge to stay steady in your convictions can be a game changer. 
Via The Motley Fool
3 Dividend Stocks to Buy for a Recession-Proof Portfolio
Many investors believe we’re at the point of no return, leading us to look at some of the best dividend stocks for a recession. 
Via InvestorPlace
3 Dividend Stocks to Buy and Hold for the Next Decade
Long-term investors looking for income should especially like these stocks. 
Via The Motley Fool
AbbVie Stock Shows Improved Relative Price Strength
AbbVie stock had its Relative Strength Rating upgraded from 69 to 76 Thursday, but still shy of the 80 or higher score you prefer to see. 
Via Investor's Business Daily
Check Out What Whales Are Doing With ABBV
Via Benzinga
Why 2023 Could Be a Tough Year for AbbVie Stock
Should you buy the stock despite its headwinds? 
Via The Motley Fool
FDA Strikes Down Eli Lilly's Application Seeking Approval For Ulcerative Colitis Drug
Via Benzinga
Why Next Week's Earnings Report is Good for Johnson & Johnson
Investors have had to digest some negative news headlines, but if you look past that a dividend king like JNJ can be a boring but reliable buy in this market 
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property
2 Forever Stocks to Buy No Matter What the Market Is Doing
These two top stocks are trading at very reasonable prices right now. 
Via The Motley Fool
5 High-Yield Dividend Stocks in Warren Buffett's Secret Portfolio You Can Buy Right Now
The dividend yields for these Buffett stocks range from 3.7% to 10.6%. 
Via The Motley Fool
AbbVie, Thermo Fisher Scientific And A Must-Watch Biotech ETF: CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Bryn Talkington of Requisite Capital Management said she is sticking with AbbVie Inc. (NYSE: ABBV), which has a 7.3% free cash flow yiel 
Via Benzinga
The Latest Analyst Ratings for AbbVie
Via Benzinga
This Is What Whales Are Betting On AbbVie
Via Benzinga
AbbVie Unusual Options Activity
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 5, 2023
Via Benzinga
Better Dividend Stock: AbbVie vs. Johnson & Johnson
Both companies have a lot to offer income-seekers. 
Via The Motley Fool
Want to Collect Big Dividends Each Month? Buy These 3 Stocks
These stocks could provide your portfolio with a reliable foundation for growing passive income. 
Via The Motley Fool
Large Cap Biopharmaceuticals Q1 2023: In This Bullish Run Biotech Lags
It was very difficult to make money in Q1 trading healthcare or biotech ETFs because of the sharp rally in other sectors. Nonetheless, there were two big winners. 
Via Talk Markets
These 5 High-Yield Dividend Stocks Should Make Me $3,000 in Passive Income This Year
The dividends should increase for several of these stocks. 
Via The Motley Fool
Week In Review: Apollomics Merges With SPAC To Support Candidates Targeting Difficult-To-Treat Cancers
Apollomics, Inc., a US-China biopharma, merged with a SPAC to list on the Nasdaq exchange. At the merger price of $10/share, Apollomics had a market cap of about $900 million, but the shares have... 
Via Talk Markets
Could This Drug News Lift AbbVie's Stock?
Alongside Skyrizi, the immunology medicine is part of AbbVie's bright post-Humira future. 
Via The Motley Fool
The Top Healthcare Stocks to Buy With $100
With the right stocks, even a small investment can yield huge returns. 
Via The Motley Fool
ImmuneOnco Banks On Cutting-edge Cancer Drugs To Attract IPO Cash
Key Takeaways: ImmuneOnco’s main product pipeline is a cancer drug targeting a promising protein pathway, the first such drug to enter clinical tests in China, with more intensive trials due in the... 
Via Benzinga
This Blockbuster Drug's Latest News Could Be Another Home Run for AbbVie
This medicine is approved for three indications in the U.S. and is well on its way to another. 
Via The Motley Fool
2 High-Yielding Dividend Investments to Buy for the Long Haul
Both of these stocks are Dividend Kings, and their payouts are likely to continue rising in the future. 
Via The Motley Fool
Better Growth Stock: Vertex Pharmaceuticals vs. AbbVie
These stocks look reasonably priced considering their future prospects. 
Via The Motley Fool
Better Growth Stock: AbbVie vs. Pfizer
One of the pair will have trouble challenging its recent heights. 
Via The Motley Fool
< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
71 72 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.